Monte Rosa Therapeutics will present preclinical data on MRT-8102, its NEK7-directed molecular glue degrader for gout-related inflammation, at ACR26. The update

Monte Rosa Therapeutics will present preclinical data on MRT-8102, its NEK7-directed molecular glue degrader for gout-related inflammation, at ACR26. The update extends its inflammation pipeline as the company also advances MRT-6160 in Phase 2.